HER2 in NSCLC: Advances and Insights With Dr. Julia Kathleen Rotow

23 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Claim your credit here: https://bit.ly/3xXotjt

Explore the evolving landscape of HER2-mutated non–small cell lung cancer (NSCLC) treatment with Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute. In this interview, Dr. Rotow provides updates on HER2-targeted therapies, the importance of continuing medical education, and the future of HER2 in NSCLC care.

Learn more about i3 Health’s educational activity, What’s New with HER2: Charting New Paths in NSCLC Care, and stay informed on the latest advancements in HER2-mutated NSCLC treatment.

#HER2NSCLC #LungCancerCare #OncologyEducation #HER2Therapies #NSCLCAdvances #CancerResearch #TargetedTherapies #ThoracicOncology #CMEActivity #OncologyInnovation
Categoria
Oncology
Commenta per primo questo video.

Prossimo